Screen 8 APAC markets for data-localisation friction.
Atlas quick-scans 8 APAC markets filtered for data-localisation laws and healthcare AI regulation. It surfaces Singapore and Australia as lowest-friction entry points, and flags Japan’s 18+ month PMDA approval path, saving months of misdirected legal spend.
Run Atlas- 1
Describe the task
Atlas can Quick-Scan a wide field of markets against a single regulatory filter and rank them by entry friction, so you can shortlist where the legal path is short before you brief a lawyer. Its regulatory agent reads data-localisation laws and sector-specific approval regimes for each market and returns a friction score plus a timeline flag, ready to narrow into a deeper side-by-side comparison of the top few.
The more specific your filter, the more useful the screen. Tell Atlas your sector, the regulations that matter, and the approval paths you can’t afford to hit, and it will surface the low-friction entry points and flag the multi-year approvals early.
Quick-scan 8 APAC markets (Singapore, Australia, Japan, South Korea, India, Indonesia, Vietnam, Philippines) for our healthcare AI product. Filter each market for: - Data-localisation laws affecting patient data storage and processing - Healthcare AI / medical-device regulation and the approval path required - Estimated time-to-approval for a product like ours Rank the 8 by regulatory friction, lowest first. Flag any market where approval is likely to exceed 12 months, and name the lowest-friction entry points so I can take the top few into a deeper side-by-side comparison.
- 2
Give Atlas context
In an Atlas workspace, name the markets and the regulatory dimensions that gate your product. Atlas applies the same filter to every market it Quick-Scans, so the friction scores stay comparable across the eight rather than reading as eight separate legal summaries: a shortlist you can narrow to a deeper comparison of the top few.
Be explicit about what your product touches, patient data, diagnostic claims, on-device inference. A healthcare AI that stores patient records faces a different regime than one that only assists clinicians, and the screen is only as accurate as that detail.
Required contextThe list of markets to screen, here 8 APAC marketsYour regulatory filter, data-localisation and healthcare AI approval for this runOptional contextA product data-flow note, what patient data is stored, processed, or sent off-deviceYour target launch date, so Atlas can flag markets whose approval path won’t fitA note on any existing certifications you hold that may shorten a pathproduct-dataflow.mdapac-market-list.csvexisting-certs.pdf - 3
What Atlas creates
Atlas returns the 8 markets ranked by regulatory friction, each with a data-localisation read, an approval-path summary, and a timeline flag. The low-friction entry points rise to the top; the multi-year approvals are flagged so they never quietly consume a launch timeline.
From Atlas: Quick-scanned 8 APAC markets against the data-localisation and healthcare-AI filter in product-dataflow.md.
8Markets Quick-Scanned to a shortlist2Low-friction entry points18+ moLongest approval path flaggedLow friction, enter first2 marketsMarket Friction score Approval path Est. timeline Singapore 18 HSA notification, clear digital-health guidance 3-4 months Australia 24 TGA pathway, established SaMD framework 4-6 months High friction, plan around2 marketsMarket Friction score Flag Japan 79 PMDA approval path likely 18+ months, strict localisation South Korea 68 MFDS review plus data-residency requirements, 12+ months "Singapore and Australia are your clean entry points, both under six months. Japan’s PMDA path is 18-plus months and would stall a 2026 launch, worth deferring. Want the full regulatory checklist for Singapore, or a deeper read on Japan’s timeline?"
- 4
Follow-up prompts
Build the checklist for the top market
Once Singapore ranks first, Atlas can expand it into a step-by-step compliance checklist, HSA notification requirements, data-residency setup, and the documents you’ll need to file.
Build the full regulatory entry checklist for Singapore: HSA notification steps, patient-data residency requirements, and the exact documentation we need to prepare, in filing order.
Pressure-test the Japan timeline
Before writing off a large market, Atlas can dig deeper into the flagged long approval path to confirm whether it’s truly 18 months or shortenable with an existing certification.
Do a deep read on Japan’s PMDA approval path for our product. Confirm the 18-month estimate, and tell me whether any certification we already hold could shorten it.
Re-screen with a new constraint
Filters change as strategy sharpens. Atlas can re-run the same 8 markets with an added constraint, like reimbursement pathways, and re-rank on the fuller picture.
Re-screen the same 8 markets, but add public-reimbursement availability for healthcare AI as a scoring dimension, then re-rank all eight.
- 5
Tips and troubleshooting
Describe the data your product touches
Localisation risk hinges on whether you store patient data, process it in-region, or only assist a clinician on-device. Spell that out, or the friction scores will be conservative guesses.
Timeline flags protect your launch date
The most expensive regulatory surprise is a hidden multi-year approval. Ask Atlas to flag anything over your launch window explicitly, so a slow market is deferred by choice, not discovered late.
Screen wide, then go deep
The screen is a fast filter across many markets, not a legal opinion. Use it to shortlist, then run a deep read on the two or three that survive before committing legal spend.
Ready to try it yourself?
Set your regulatory filter once and let Atlas rank a whole region by entry friction, so you spend legal budget on the markets that will actually clear.
Run Atlas